Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018

  • ID: 4576093
  • Drug Pipelines
  • 61 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • EndoCeutics Inc
  • MenoGeniX Inc
  • Mithra Pharmaceuticals SA
  • Ogeda SA
  • TherapeuticsMD Inc
  • MORE
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Report Highlights:

This latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 5, 2, 1 and 2 respectively.

Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • EndoCeutics Inc
  • MenoGeniX Inc
  • Mithra Pharmaceuticals SA
  • Ogeda SA
  • TherapeuticsMD Inc
  • MORE
Introduction

Report Coverage

Vasomotor Symptoms of Menopause (Hot Flashes) - Overview

Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Vasomotor Symptoms of Menopause (Hot Flashes) - Drug Profiles

acolbifene hydrochloride + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MNGX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80HF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-001HR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-006HR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-008HR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects

Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products

Vasomotor Symptoms of Menopause (Hot Flashes) - Product Development Milestones

Featured News & Press Releases

May 30, 2018: Mithra Announces Further Positive Phase IIb Donesta Efficacy and Safety Data

May 03, 2018: MenoGeniX Awarded NIH Grant to Fund Phase Ib/IIa Clinical Trial

Apr 19, 2018: Mithra Announces Positive Donesta Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile

Apr 17, 2018: Clinical Trial Begins For Promising New Post-Menopausal Therapy Treating Vasomotor Symptoms

Mar 08, 2018: TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR

Jan 25, 2018: Mithra Announces Last Subject Completes Donesta Phase II Study

Dec 28, 2017: New Menopause Therapy from Fervent Pharmaceuticals to Begin Clinical Trial

Dec 28, 2017: TherapeuticsMD Announces Submission of New Drug Application for TX-001HR

Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS 2017

Sep 27, 2017: Kandy Therapeutics Launched To Focus On A Breakthrough New Product in Women's Health

Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017

Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364

Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • EndoCeutics Inc
  • MenoGeniX Inc
  • Mithra Pharmaceuticals SA
  • Ogeda SA
  • Pherin Pharmaceuticals Inc
  • TherapeuticsMD Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll